Want to see DRIO full AI Analyst Report?
Top Page
DarioHealth
(NASDAQ:DRIO)
Select Model
Select Model
Rating:46Neutral
Price Target:
$3.50
▼(-52.64% Downside)
Action:Reiterated
Date:10/24/26
DRIO scores low primarily due to weak financial performance (sharp recent revenue decline, persistent operating losses, and ongoing negative free cash flow) and bearish technicals (price far below major moving averages with negative MACD). These negatives are partially offset by a low P/E and a more positive earnings-call outlook centered on contracted ARR conversion, margin expansion, tighter expenses, and improved cash runway, but the timing lag to revenue realization keeps risk high.
Positive Factors
Contracted ARR Pipeline
The contracted ARR base provides a visible foundation for future revenue, while the predominance of multi-condition programs may deepen account penetration and increase customer value. As implementations and enrollments progress, this pipeline could support more durable growth than relying solely on new account wins.
Negative Factors
Sharp Revenue Contraction
The steep TTM revenue decline shows that commercial momentum has not yet translated into recognized sales and materially weakens the current operating base. Even if management’s pipeline converts, rebuilding scale will take time and leaves the company exposed to execution risk during the transition.
Read all positive and negative factors
Positive Factors
Negative Factors
Contracted ARR Pipeline
The contracted ARR base provides a visible foundation for future revenue, while the predominance of multi-condition programs may deepen account penetration and increase customer value. As implementations and enrollments progress, this pipeline could support more durable growth than relying solely on new account wins.
Read all positive factors
DarioHealth (DRIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$36.94M
Dividend YieldN/A
Average Volume (3M)39.60K
Price to Earnings (P/E)5.5
Beta (1Y)0.23
Revenue Growth-22.65%
EPS Growth62.36%
CountryUS
Employees163
SectorHealthcare
Sector Strength45
IndustryMedical - Specialties
Share Statistics
EPS (TTM)1.26
Shares Outstanding9,799,481
10 Day Avg. Volume77,736
30 Day Avg. Volume39,605
Financial Highlights & Ratios
PEG Ratio-1.49
Price to Book (P/B)8.32
Price to Sales (P/S)25.26
P/FCF Ratio-21.65
Enterprise Value/Market Cap2.16
Enterprise Value/Revenue3.80
Enterprise Value/Gross Profit6.78
Enterprise Value/Ebitda-2.68
Forecast
1Y Price Target
$10.00Price Target Upside35.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.98
Revenue Forecast (FY)$21.71M
DarioHealth Business Overview & Revenue Model
Company Description
DarioHealth Corp. is a digital therapeutics enterprise operating across the United States, Canada, the European Union, Australia, and New Zealand. The company delivers a suite of digital health solutions, including its 'Dario' metabolic programs d...
How the Company Makes Money
DarioHealth primarily generates revenue by selling access to its digital health platform and condition-management programs to organizational customers (e.g., employers, health plans, and other healthcare entities) under commercial arrangements tha...
DarioHealth Earnings Call Summary
Earnings Call Date:Aug 11, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Nov 16, 2026
Earnings Call Sentiment Positive
The call emphasized meaningful operational progress: stronger gross margins, disciplined expense reductions, improvement in net loss, a sizable ARR pipeline ($13.1M) that is predominantly multi-condition, a strengthened cash position (~$36.8M pro forma), and product/AI-driven commercialization (DarioIQ, GLP-1, Dario Women, Dario Sleep). The principal near-term concern is a modest decline in reported revenue due to strategic channel transitions and the multi-quarter lag between contract signings and recognized recurring revenue. Management framed these as temporary/timing issues while highlighting durable improvements in margin, efficiency, and the quality of future revenue. Overall, the positives around margin expansion, expense discipline, sales pipeline quality, AI/data advantages, and cash runway materially outweigh the near-term topline timing headwinds.Positive Updates
Recurring Revenue and Contracted ARR Pipeline
Contracted and late-stage annual recurring revenue (ARR) of approximately $13.1 million, with more than 80% of that ARR multi-condition, positioning future revenue conversion as implementations and enrollments progress.
Negative Updates
Sequential and Year-over-Year Revenue Decline
Reported revenue for Q2 2026 was $5.2 million, down from $5.6 million in Q1 2026 (≈ -7.1% sequential) and down from $5.4 million in Q2 2025 (≈ -3.7% year-over-year). Management attributes decline to timing of implementations and strategic exit from pharmaceutical services.
Read all updates
Q2-2026 Updates
Positive
Negative
Recurring Revenue and Contracted ARR Pipeline
Contracted and late-stage annual recurring revenue (ARR) of approximately $13.1 million, with more than 80% of that ARR multi-condition, positioning future revenue conversion as implementations and enrollments progress.
Read all positive updates
Company Guidance
Management guided that the company’s $13.1 million of contracted and late‑stage ARR is expected to convert into recognized revenue over a typical 4–5 quarter implementation cycle (beginning in H2 2026 with the majority of contribution in 2027), and that DarioIQ could drive an incremental ~10–15% in recurring revenue from existing customers over time; they expect accelerated revenue growth in the back half of 2026 and into 2027 driven by channel-led deals (75% of new accounts), 180+ signed accounts (including five Fortune 50 customers and ~25% of B2B2C clients from the Fortune 500), and >80% of contracted ARR already multi‑condition, supported by a newly launched GLP‑1 provider‑backed program and new Women and Sleep offerings expected to begin contributing in Q4; financially, Q2 revenue was $5.2M (vs. $5.6M Q1 and $5.4M LY), gross margin rose to 62% (non‑GAAP B2B2C gross margin ~80%), operating expenses fell 8% sequentially and 21% YoY, operating loss improved 11% Q/Q and 30% YoY, net loss narrowed to $7.9M (down 39% YoY), and pro forma cash stood at $36.8M ($14M on hand plus $22.8M net from the July financing) to fund the planned scaling.DarioHealth Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
56
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 21.00M | 22.36M | 27.04M | 20.35M | 27.66M | 20.51M |
| Gross Profit | 11.78M | 12.66M | 13.27M | 5.98M | 9.65M | 8.07M |
| EBITDA | -29.75M | -35.11M | -37.08M | -54.38M | -55.60M | -70.02M |
| Net Income | 67.78M | -41.71M | -42.75M | -59.43M | -62.19M | -76.76M |
Balance Sheet | ||||||
| Total Assets | 96.59M | 110.08M | 118.88M | 96.39M | 119.19M | 100.77M |
| Cash, Cash Equivalents and Short-Term Investments | 14.25M | 26.25M | 28.46M | 36.80M | 49.36M | 36.00M |
| Total Debt | 32.41M | 31.75M | 30.19M | 29.54M | 28.05M | 287.00K |
| Total Liabilities | 41.50M | 42.15M | 46.87M | 38.24M | 39.19M | 15.22M |
| Stockholders Equity | 55.09M | 67.92M | 72.02M | 58.14M | 80.00M | 85.55M |
Cash Flow | ||||||
| Free Cash Flow | -24.89M | -26.08M | -38.70M | -30.96M | -48.42M | -50.67M |
| Operating Cash Flow | -24.75M | -25.94M | -38.56M | -30.38M | -47.84M | -50.41M |
| Investing Cash Flow | -7.38M | -4.34M | -8.93M | -547.00K | -573.00K | -8.13M |
| Financing Cash Flow | 17.37M | 24.31M | 38.53M | 18.25M | 61.94M | 65.77M |
DarioHealth Technical Analysis
Negative
7.39
Price Trends
6.38
Negative
6.75
Negative
7.96
Negative
Market Momentum
-0.78
Positive
27.71
Positive
18.73
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DRIO, the sentiment is Negative. The current price of 7.39 is above the 20-day moving average (MA) of 5.37, above the 50-day MA of 6.38, and below the 200-day MA of 7.96, indicating a bearish trend. The MACD of -0.78 indicates Positive momentum. The RSI at 27.71 is Positive, neither overbought nor oversold. The STOCH value of 18.73 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DRIO.
DarioHealth Risk Analysis
DarioHealth disclosed 48 risk factors in its most recent earnings report. DarioHealth reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
DarioHealth Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $3.85B | 33.28 | 8.64% | ― | 17.28% | 323.64% | |
55 Neutral | $293.87M | -4.17 | -49.17% | 2.46% | 182.05% | -5.43% | |
53 Neutral | $556.68M | -4.87 | -32.59% | 13.45% | -3.16% | 72.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $553.06M | -7.13 | -7.87% | ― | 6.83% | -69.59% | |
46 Neutral | $36.94M | 5.46 | 104.15% | ― | -22.65% | 62.36% | |
42 Neutral | $4.71M | -0.16 | 48.72% | 1.23% | -13.28% | 39.65% |
* Healthcare Sector Average
DRIO
DarioHealth
3.77
-11.98
-76.06%
MYGN
Myriad Genetics
5.82
-2.28
-28.15%
TRIB
Trinity Biotech
7.30
-23.30
-76.15%
VCYT
Veracyte
47.93
11.96
33.25%
FLGT
Fulgent Genetics
20.10
-3.21
-13.77%
PRE
Prenetics Group
17.35
4.27
32.65%
DarioHealth Corporate Events
Business Operations and StrategyExecutive/Board Changes
DarioHealth announces board member retirement, governance remains stable
Neutral
Sep 4, 2026
On September 2, 2026, DarioHealth Corp. announced that board member Lawrence Leisure retired from the Board of Directors, effective the same day. The company stated that Leisure’s departure was for personal reasons and did not stem from any ...
Business Operations and StrategyExecutive/Board Changes
DarioHealth Announces Executive Leadership Transition and Consulting Role
Neutral
Aug 21, 2026
DarioHealth Corp. announced leadership changes following the previously disclosed temporary medical leave of Steven Nelson, its President and Chief Commercial Officer, which was extended indefinitely on July 10, 2026. On August 20, 2026, the compa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.